Evidence map›Paper›PMID 41040222›Full record

ArticlebioRxiv : the preprint server for biology2025

Dual Modes of Gene Regulation by CDK12.

Yubao Wang, Apoorva Baluapuri, Cherubin Manokaran, Jing Ni, Tao Jiang, Roel C Janssens, Jurgen A Marteijn, Karen Adelman, Jean Zhao, Thomas M Roberts

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yubao WangDepartments of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Apoorva BaluapuriDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Cherubin ManokaranDepartments of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Jing NiDepartments of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Tao JiangDepartments of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Roel C JanssensDepartment of Molecular Genetics, Oncode Institute, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, the Netherlands.
Jurgen A MarteijnDepartment of Molecular Genetics, Oncode Institute, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, the Netherlands.ORCID 0000-0001-9321-518X
Karen AdelmanDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Jean ZhaoDepartments of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Thomas M RobertsDepartments of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

Funding

Integrating targeted therapy and immunotherapy to break through cancerR35CA210057 · NCI · DANA-FARBER CANCER INST · PI Jean Zhao · 2016 to 2026
$10.8M
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null CancersR35CA231945 · NCI · DANA-FARBER CANCER INST · PI ROBERTS, THOMAS M · 2019 to 2025
$7.1M
NCI NIH HHS R35 CA210057NCI NIH HHS R35 CA231945
6 · The paper itself

Abstract

The process of transcription is driven forward by the activity of kinases including CDK7, CDK9 and CDK12. Accordingly, acute inhibition of any of these kinases results in profound downregulation of gene expression. Here, we discover that loss or inhibition of CDK12 also significantly upregulates a set of coding and non-coding loci, whose activation could contribute to the anti-proliferative effects of CDK12 inhibitors. Mechanistically, CDK12 inhibition impairs transcription elongation, leading to increased RNA polymerase II termination or arrest in long genes. However, short genes such as MYC and enhancer RNAs are highly transcribed in the absence of CDK12 activity. Indeed, in HER2+ breast cancer, a malignancy where CDK12 is co-amplified with HER2 and its expression correlates with disease status, CDK12 inhibition markedly elevates MYC expression to induce lethality. The dual effects of CDK12 inhibition elucidated herein clarify its role in transcriptional control and have significant translational implications.

Identifiers

PMID41040222
PMCPMC12485715

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.